Biomolecular markers in assessment and treatment of asthma

Respirology

Volumn 19, Issue 4, 2014, Pages 514-523

  Fatemi, Farnaz ^a   Sadroddiny, Esmaeil ^a   Gheibi, Azam ^a   Mohammadi Farsani, Taiebeh ^a   Kardar, Gholam Ali ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

asthma; biomarker; eosinophil; inflammation; molecular targeted therapy

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; MOLECULAR MARKER; NITRIC OXIDE; ANTIINFLAMMATORY AGENT;

ALLERGIC AIRWAY INFLAMMATION; ASTHMA; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; EARLY DIAGNOSIS; EXPIRED AIR; GAS ANALYSIS; HUMAN; LUNG FUNCTION TEST; NON INVASIVE PROCEDURE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SPUTUM; SPUTUM ANALYSIS; URINE LEVEL; DRUG MONITORING; ENDOPHENOTYPE; INFLAMMATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PROCEDURES; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRENDS;

ANTI-INFLAMMATORY AGENTS; ASTHMA; BIOLOGICAL MARKERS; DRUG MONITORING; EARLY DIAGNOSIS; ENDOPHENOTYPES; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84899125098     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12284     Document Type: Review

References (101)

1. Bousquet J, Khaltaev NG,. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. World Health Organization, Geneva, 2007.
2. Fahy JV,. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc. Am. Thorac. Soc. 2009; 6: 256-259.
3. Taylor DR,. Biomarkers of inflammation in asthma: a clinical perspective. Semin. Respir. Crit. Care Med. 2012; 33: 620-629.
4. Murugan A, Prys-Picard C, Calhoun WJ,. Biomarkers in asthma. Curr. Opin. Pulm. Med. 2009; 15: 12-18.
5. Wadsworth S, Sin D, Dorscheid D,. Clinical update on the use of biomarkers of airway inflammation in the management of asthma. J. Asthma. Allergy. 2011; 4: 77-86.
6. Cao W, Duan Y,. Breath analysis: potential for clinical diagnosis and exposure assessment. Clin. Chem. 2006; 52: 800-811.
7. Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, Pavord ID, Ratjen F, Silkoff PE, Taylor DR, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010; 138: 682-692.
8. Brindicci C, Ito K, Barnes PJ, Kharitonov SA,. Effect of an inducible nitric oxide synthase inhibitor on differential flow-exhaled nitric oxide in asthmatic patients and healthy volunteers. Chest 2007; 132: 581-588.
9. Klebanoff SJ,. Reactive nitrogen intermediates and antimicrobial activity: role of nitrite. Free Radic. Biol. Med. 1993; 14: 351-360.
10. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am. J. Respir. Crit. Care Med. 2005; 171: 912-930.
11. Dressel H, de la Motte D, Reichert J, Ochmann U, Petru R, Angerer P, Holz O, Nowak D, Jorres RA,. Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height. Respir. Med. 2008; 102: 962-969.
12. Tseliou E, Bessa V, Hillas G, Delimpoura V, Papadaki G, Roussos C, Papiris S, Bakakos P, Loukides S,. Exhaled nitric oxide and exhaled breath condensate pH in severe refractory asthma. Chest 2010; 138: 107-113.
13. Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G, Peter Herbison G, Robin Taylor D,. Exhaled nitric oxide: a predictor of steroid response. Am. J. Respir. Crit. Care Med. 2005; 172: 453-459.
14. Powell H, Murphy VE, Taylor DR, Hensley MJ, McCaffery K, Giles W, Clifton VL, Gibson PG,. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomized controlled trial. Lancet 2011; 378: 983-990.
15. Petsky HL, Cates CJ, Li A, Kynaston JA, Turner C, Chang AB,. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database Syst. Rev. 2009; (4): CD006340.
16. Hervas D, Milan JM, Garde J,. Differences in exhaled nitric oxide in atopic children. Allergol. Immunopathol. (Madr) 2008; 36: 331-335.
17. Scott M, Raza A, Karmaus W, Mitchell F, Grundy J, Kurukulaaratchy RJ, Arshad SH, Roberts G,. Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study. Thorax 2010; 65: 258-262.
18. Grob NM, Aytekin M, Dweik RA,. Biomarkers in exhaled breath condensate: a review of collection, processing and analysis. J. Breath. Res. 2008; 2: 037004.
19. Ratnawati R, Morton J, Henry RL, Thomas PS,. Exhaled breath condensate nitrite/nitrate and pH in relation to pediatric asthma control and exhaled nitric oxide. Pediatr. Pulmonol. 2006; 41: 929-936.
20. Hunt J,. Exhaled breath condensate pH assays. Immunol. Allergy Clin. North Am. 2007; 27: 597-606.
21. Teng Y, Sun P, Zhang J, Yu R, Bai J, Yao X, Huang M, Adcock IM, Barnes PJ,. Hydrogen peroxide in exhaled breath condensate in patients with asthma: a promising biomarker? Chest 2011; 140: 108-116.
22. Pinkerton M, Chinchilli V, Banta E, Craig T, August A, Bascom R, Cantorna M, Harvill E, Ishmael FT,. Differential expression of microRNAs in exhaled breath condensates of patients with asthma, patients with chronic obstructive pulmonary disease, and healthy adults. J. Allergy Clin. Immunol. 2013; 132: 217-292.
23. Mondino C, Ciabattoni G, Koch P, Pistelli R, Trove A, Barnes PJ, Montuschi P,. Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. J. Allergy Clin. Immunol. 2004; 114: 761-767.
24. Montuschi P, Mondino C, Koch P, Barnes PJ, Ciabattoni G,. Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J. Allergy Clin. Immunol. 2006; 118: 347-353.
25. Kostikas K, Papatheodorou G, Psathakis K, Panagou P, Loukides S,. Prostaglandin E2 in the expired breath condensate of patients with asthma. Eur. Respir. J. 2003; 22: 743-747.
26. Huszar E, Szabo Z, Jakab A, Barta I, Herjavecz I, Horvath I,. Comparative measurement of thromboxane A2 metabolites in exhaled breath condensate by different immunoassays. Inflamm. Res. 2005; 54: 350-355.
27. Montuschi P, Barnes PJ,. Exhaled leukotrienes and prostaglandins in asthma. J. Allergy Clin. Immunol. 2002; 109: 615-620.
28. Pelclova D, Fenclova Z, Kacer P, Kuzma M, Navratil T, Lebedova J,. Increased 8-isoprostane, a marker of oxidative stress in exhaled breath condensate in subjects with asbestos exposure. Ind. Health 2008; 46: 484-489.
29. Matsunaga K, Yanagisawa S, Ichikawa T, Ueshima K, Akamatsu K, Hirano T, Nakanishi M, Yamagata T, Minakata Y, Ichinose M,. Airway cytokine expression measured by means of protein array in exhaled breath condensate: correlation with physiologic properties in asthmatic patients. J. Allergy Clin. Immunol. 2006; 118: 84-90.
30. Zietkowski Z, Skiepko R, Tomasiak MM, Bodzenta-Lukaszyk A,. Endothelin-1 in exhaled breath condensate of allergic asthma patients with exercise-induced bronchoconstriction. Respir. Res. 2007; 8: 76.
31. Csoma Z, Huszar E, Vizi E, Vass G, Szabo Z, Herjavecz I, Kollai M, Horvath I,. Adenosine level in exhaled breath increases during exercise-induced bronchoconstriction. Eur. Respir. J. 2005; 25: 873-878.
32. Zietkowski Z, Tomasiak-Lozowska MM, Skiepko R, Zietkowska E, Bodzenta-Lukaszyk A,. Eotaxin-1 in exhaled breath condensate of stable and unstable asthma patients. Respir. Res. 2010; 11: 110.
33. Karakoc GB, Yukselen A, Yilmaz M, Altintas DU, Kendirli SG,. Exhaled breath condensate MMP-9 level and its relationship with asthma severity and interleukin-4/10 levels in children. Ann. Allergy Asthma Immunol. 2012; 108: 300-304.
34. Garcia G, Bergna M, Uribe E, Yanez A, Soriano JB,. Increased exhaled breath temperature in subjects with uncontrolled asthma. Int. J. Tuberc. Lung Dis. 2013; 17: 969-972.
35. Melo RE, Popov TA, Sole D,. Exhaled breath temperature, a new biomarker in asthma control: a pilot study. J. Bras. Pneumol. 2010; 36: 693-699.
36. Dasgupta A, Nair P,. When are biomarkers required in the management of airway diseases? Pol. Arch. Med. Wewn. 2013; 123: 183-188.
37. Louis R, Sele J, Henket M, Cataldo D, Bettiol J, Seiden L, Bartsch P,. Sputum eosinophil count in a large population of patients with mild to moderate steroid-naive asthma: distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy 2002; 57: 907-912.
38. in't Veen JC, Smits HH, Hiemstra PS, Zwinderman AE, Sterk PJ, Bel EH,. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am. J. Respir. Crit. Care Med. 1999; 160: 93-99.
39. Choi JS, Jang AS, Park JS, Park SW, Paik SH, Park JS, Uh ST, Kim YH, Park CS,. Role of neutrophils in persistent airway obstruction due to refractory asthma. Respirology 2012; 17: 322-329.
40. Bakakos P, Schleich F, Alchanatis M, Louis R,. Induced sputum in asthma: from bench to bedside. Curr. Med. Chem. 2011; 18: 1415-1422.
41. Hemelaers L, Henket M, Sele J, Bureau F, Louis R,. Cysteinyl-leukotrienes contribute to sputum eosinophil chemotactic activity in asthmatics. Allergy 2006; 61: 136-139.
42. Kowal K, Zukowski S, Moniuszko M, Bodzenta-Lukaszyk A,. Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients. Folia Histochem. Cytobiol. 2008; 46: 193-198.
43. Mostafa GA, Reda SM, Abd El-Aziz MM, Ahmed SA,. Sputum neurokinin A in Egyptian asthmatic children and adolescents: relation to exacerbation severity. Allergy 2008; 63: 1244-1247.
44. Kodric M, Shah AN, Fabbri LM, Confalonieri M,. An investigation of airway acidification in asthma using induced sputum: a study of feasibility and correlation. Am. J. Respir. Crit. Care Med. 2007; 175: 905-910.
45. Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST,. Airway remodeling in asthma: new insights. J. Allergy Clin. Immunol. 2003; 111: 215-225; quiz 26.
46. Mattos W, Lim S, Russell R, Jatakanon A, Chung KF, Barnes PJ,. Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids. Chest 2002; 122: 1543-1552.
47. Yamaguchi M, Niimi A, Matsumoto H, Ueda T, Takemura M, Matsuoka H, Jinnai M, Otsuka K, Oguma T, Takeda T, et al. Sputum levels of transforming growth factor-beta1 in asthma: relation to clinical and computed tomography findings. J. Investig. Allergol. Clin. Immunol. 2008; 18: 202-206.
48. Nomura A, Uchida Y, Sakamoto T, Ishii Y, Masuyama K, Morishima Y, Hirano K, Sekizawa K,. Increases in collagen type I synthesis in asthma: the role of eosinophils and transforming growth factor-beta. Clin. Exp. Allergy 2002; 32: 860-865.
49. Amlani S, Nadarajah T, McIvor RA,. Montelukast for the treatment of asthma in the adult population. Expert Opin. Pharmacother. 2011; 12: 2119-2128.
50. Durrani SR, Viswanathan RK, Busse WW,. What effect does asthma treatment have on airway remodeling? Current perspectives. J. Allergy Clin. Immunol. 2011; 128: 439-448; quiz 49-50.
51. Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, Hunt JF, Kita H, Liu AH, Panettieri RA Jr, et al. Asthma outcomes: biomarkers. J. Allergy Clin. Immunol. 2012; 129: S9-23.
52. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N,. Omalizumab is effective in the long-term control of severe allergic asthma. Ann. Allergy Asthma Immunol. 2003; 91: 154-159.
53. Kim CK, Callaway Z, Fletcher R, Koh YY,. Eosinophil-derived neurotoxin in childhood asthma: correlation with disease severity. J. Asthma 2010; 47: 568-573.
54. Massanari M, Holgate ST, Busse WW, Jimenez P, Kianifard F, Zeldin R,. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir. Med. 2010; 104: 188-196.
55. Verrills NM, Irwin JA, He XY, Wood LG, Powell H, Simpson JL, McDonald VM, Sim A, Gibson PG,. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011; 183: 1633-1643.
56. Yamamoto M, Singh A, Ruan J, Gauvreau GM, Byrne PMO, Carlsten CR, FitzGerald JM, Boulet LP, Tebbutt SJ,. Decreased miR-192 expression in peripheral blood of asthmatic individuals undergoing an allergen inhalation challenge. BMC Genomics 2012; 13: 655.
57. Mosca T, Menezes MC, Dionigi PC, Stirbulov R, Forte WC,. C3 and C4 complement system components as biomarkers in the intermittent atopic asthma diagnosis. J. Pediatr. (Rio J.) 2011; 87: 512-516.
58. Patil SP, Wisnivesky JP, Busse PJ, Halm EA, Li XM,. Detection of immunological biomarkers correlated with asthma control and quality of life measurements in sera from chronic asthmatic patients. Ann. Allergy Asthma Immunol. 2011; 106: 205-213.
59. Ciprandi G, Cuppari C, Salpietro AM, Tosca MA, Rigoli L, Grasso L, La Rosa M, Marseglia GL, Del Giudice MM, Salpietro C,. Serum IL-23 strongly and inversely correlates with FEV1 in asthmatic children. Int. Arch. Allergy Immunol. 2012; 159: 183-186.
60. Zhao JJ, Yang L, Zhao FQ, Shi SM, Tan P,. Osteopontin levels are elevated in patients with asthma. J. Int. Med. Res. 2011; 39: 1402-1407.
61. Saad-El-Din Bessa S, Abo El-Magd GH, Mabrouk MM,. Serum chemokines RANTES and monocyte chemo attractant protein-1 in Egyptian patients with atopic asthma: relationship to disease severity. Arch. Med. Res. 2012; 43: 36-41.
62. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, Hamid Q, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J. Allergy Clin. Immunol. 2012; 130: 647-54 e10.
63. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 2011; 365: 1088-1098.
64. Tang H, Fang Z, Sun Y, Li B, Shi Z, Chen J, Zhang T, Xiu Q,. YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E. Eur. Respir. J. 2010; 35: 757-760.
65. Specjalski K, Jassem E,. YKL-40 protein is a marker of asthma. J. Asthma 2011; 48: 767-772.
66. Ezzat MH, Imam SS, Shaheen KY, Elbrhami EM,. Serum OX40 ligand levels in asthmatic children: a potential biomarker of severity and persistence. Allergy Asthma Proc. 2011; 32: 313-318.
67. Tanju A, Cekmez F, Aydinoz S, Karademir F, Suleymanoglu S, Gocmen I,. Association between clinical severity of childhood asthma and serum leptin levels. Indian J. Pediatr. 2011; 78: 291-295.
68. Sampson AP,. The leukotrienes: mediators of chronic inflammation in asthma. Clin. Exp. Allergy 1996; 26: 995-1004.
69. Severien C, Artlich A, Jonas S, Becher G,. Urinary excretion of leukotriene E4 and eosinophil protein X in children with atopic asthma. Eur. Respir. J. 2000; 16: 588-592.
70. Suzuki N, Hishinuma T, Abe F, Omata K, Ito S, Sugiyama M, Mizugaki M,. Difference in urinary LTE4 and 11-dehydro-TXB2 excretion in asthmatic patients. Prostaglandins Other Lipid Mediat. 2000; 62: 395-403.
71. Higashi N, Mita H, Ono E, Fukutomi Y, Yamaguchi H, Kajiwara K, Tanimoto H, Sekiya K, Akiyama K, Taniguchi M,. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J. Allergy Clin. Immunol. 2010; 125: 1084-1916.
72. Shaughnessy KMO, Wellings R, Gillies B, Fuller RW,. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am. Rev. Respir. Dis. 1993; 147: 1472-1476.
73. Liu MC, Dube LM, Lancaster J,. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J. Allergy Clin. Immunol. 1996; 98: 859-871.
74. Nuijsink M, Hop WC, Sterk PJ, Duiverman EJ, De Jongste JC,. Urinary eosinophil protein X in childhood asthma: relation with changes in disease control and eosinophilic airway inflammation. Mediators Inflamm. 2013; 2013: 532619.
75. O'Sullivan S, Dahlen B, Dahlen SE, Kumlin M,. Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J. Allergy Clin. Immunol. 1996; 98: 421-432.
76. Nagakura T, Obata T, Shichijo K, Matsuda S, Sigimoto H, Yamashita K, Masaki T, Maekawa K,. GC/MS analysis of urinary excretion of 9 alpha, 11 beta-PGF2 in acute and exercise-induced asthma in children. Clin. Exp. Allergy 1998; 28: 181-186.
77. Misso NL, Aggarwal S, Phelps S, Beard R, Thompson PJ,. Urinary leukotriene E4 and 9 alpha, 11 beta-prostaglandin F concentrations in mild, moderate and severe asthma, and in healthy subjects. Clin. Exp. Allergy 2004; 34: 624-631.
78. Wu W, Chen Y, d'Avignon A, Hazen SL,. 3-Bromotyrosine and 3, 5-dibromotyrosine are major products of protein oxidation by eosinophil peroxidase: potential markers for eosinophil-dependent tissue injury in vivo. Biochemistry 1999; 38: 3538-3548.
79. Wedes SH, Wu W, Comhair SA, McDowell KM, DiDonato JA, Erzurum SC, Hazen SL,. Urinary bromotyrosine measures asthma control and predicts asthma exacerbations in children. J. Pediatr. 2011; 159: 248-55 e1.
80. Rabe KF, Calhoun WJ, Smith N, Jimenez P,. Can anti-IgE therapy prevent airway remodeling in allergic asthma? Allergy 2011; 66: 1142-1151.
81. Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A,. Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma. Respiration 2010; 80: 534-542.
82. D'Amato G,. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. Eur. J. Pharmacol. 2006; 533: 302-307.
83. Busse W, Buhl R, Fernandez Vidaurre C, Blogg M, Zhu J, Eisner MD, Canvin J,. Omalizumab and the risk of malignancy: results from a pooled analysis. J. Allergy Clin. Immunol. 2012; 129: 983-989 e6.
84. Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L,. Churg-Strauss syndrome in patients treated with omalizumab. Chest 2009; 136: 507-518.
85. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P,. Mepolizumab for severe eosinophilic asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
86. Cho JY,. Recent advances in mechanisms and treatments of airway remodeling in asthma: a message from the bench side to the clinic. Korean J. Intern. Med. 2011; 26: 367-383.
87. Akdis CA,. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat. Med. 2012; 18: 736-749.
88. Kasaian MT, Miller DK,. IL-13 as a therapeutic target for respiratory disease. Biochem. Pharmacol. 2008; 76: 147-155.
89. Thomson NC, Patel M, Smith AD,. Lebrikizumab in the personalized management of asthma. Biologics. 2012; 6: 329-335.
90. Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A,. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm. Med. 2010; 10: 3.
91. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, Beckett P, Al Ali M, Chauhan A, Wilson SJ, et al. Tumor necrosis factor (TNF alpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60: 1012-1018.
92. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am. J. Respir. Crit. Care Med. 2006; 174: 753-762.
93. Scheinfeld N,. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J. Dermatol. Treat. 2004; 15: 280-294.
94. Kouklakis G, Efremidou EI, Pitiakoudis M, Liratzopoulos N, Polychronidis A,. Development of primary malignant melanoma during treatment with a TNF-alpha antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-alpha blockers and cancer. Drug Des. Dev. Ther. 2013; 7: 195-199.
95. Holgate ST, Noonan M, Chanez P, Busse W, Dupont L, Pavord I, Hakulinen A, Paolozzi L, Wajdula J, Zang C, et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomized, controlled trial. Eur. Respir. J. 2011; 37: 1352-1359.
96. Wegmann M,. Targeting eosinophil biology in asthma therapy. Am. J. Respir. Cell Mol. Biol. 2011; 45: 667-674.
97. Lee WT, Kirkham N, Johnson MK, Lordan JL, Fisher AJ, Peacock AJ,. Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension. Eur. Respir. J. 2011; 37: 472-474.
98. Galie N, Hoeper MM, Simon J, Gibbs R, Simonneau G,. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur. Heart J. 2011; 32: 386-387.
99. Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T,. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem. Biophys. Res. Commun. 2009; 386: 181-185.
100. Petersen BC, Lukacs NW,. IL-17A and IL-25: therapeutic targets for allergic and exacerbated asthmatic disease. Future. Med. Chem. 2012; 4: 833-836.
101. Boshier PR, Hanna GB, Marczin N,. Exhaled nitric oxide as biomarker of acute lung injury: an unfulfilled promise? J. Breath. Res. 2013; 7: 017118.